Leukemia mop-up drug trial ends early with few volunteers
NCT ID NCT01258933
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study tested whether the drug ofatumumab could control any remaining chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after initial chemotherapy. It was designed for patients whose disease had not worsened after prior treatment. The trial was terminated early and only enrolled 4 people, so results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.